Tenaya Therapeutics (TNYA) Price & Analysis

Compare

2,421 Followers

TNYA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.36 - $4.01

Previous CloseN/A

Volume1.07M

Average Volume (3M)3.15M

Market Cap

$280.32M

Enterprise Value$40.04M

Total Cash (Recent Filing)$71.67M

Total Debt (Recent Filing)$12.21M

Price to Earnings (P/E)―

Beta3.14

Next Earnings

Nov 05, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding162,976,100

10 Day Avg. Volume3,291,829

30 Day Avg. Volume3,146,495

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.14

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-19.21

Enterprise Value/Ebitda-0.43

Forecast

1Y Price Target

$10.14

Price Target Upside489.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Data ReadoutsUpcoming data readouts for gene therapy programs are expected to focus on tolerability and biopsy results, highlighting ongoing execution.

Gene Therapy AdvancementsTenaya is developing two AAV-based gene therapy approaches for the treatment of cardiomyopathies, which are expected to halt disease progression and improve symptoms after a single dose.

Protein Measurement PrecisionManagement is confident in more precise methods for detecting protein expression, setting the stage for multiple data readouts.

Bears Say

Financial StabilityTenaya Therapeutics has an annualized cash burn of $80 million with only approximately 0.9 years of cash left.

Gene Therapy ComplexityIt remains complicated to discern whether the gene therapy is working due to varying levels of endogenous protein in patients.

Tenaya Therapeutics News

Promising Developments and Strategic Approaches in Tenaya Therapeutics’ Gene Therapy Programs Drive Buy Rating

Analyst Whitney Ijem from Canaccord Genuity maintained a Buy rating on Tenaya Therapeutics and keeping the price target...

1M ago

TNYA

Promising Potential of Tenaya Therapeutics’ TN-201 Gene Therapy in Addressing Pediatric Hypertrophic Cardiomyopathy: Analyst Recommends Buy

Tenaya Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from...

1M ago

TNYA

Tenaya Therapeutics presents interim data from MyClimb natural history study

Tenaya Therapeutics (TNYA) announced the presentation of interim data from its ongoing MyClimb natural history study of pediatric...

1M ago

TNYA

Promising Advancements and Strategic Approaches Underpin Buy Rating for Tenaya Therapeutics

In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Tenaya Therapeutics,...

1M ago

TNYA

Innovative Cardiac Gene Therapy Drives Buy Rating for Tenaya Therapeutics

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Tenaya Therapeutics yesterday and set a price target...

1M ago

TNYA

Innovative Cardiac Gene Therapy Advances: Tenaya Therapeutics’ Strategic Developments and Analyst Confidence

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics today and set a price target...

1M ago

TNYA

Innovative Gene Therapy Advancements: Tenaya Therapeutics’ Breakthrough in Protein Expression Measurement

William Blair analyst Sami Corwin has maintained their bullish stance on TNYA stock, giving a Buy rating on...

1M ago

TNYA

Tenaya Therapeutics Reports Q2 2025 Financial Results

Tenaya Therapeutics, Inc. ( ($TNYA) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

TNYA

Buy Rating for Tenaya Therapeutics: Financial Stability and Promising Clinical Trial Results

TD Cowen analyst Ritu Baral has maintained their bullish stance on TNYA stock, giving a Buy rating on...

2M ago

TNYA

Promising Developments and Strong Financial Position Drive Buy Rating for Tenaya Therapeutics

Analyst Michael Ulz from Morgan Stanley maintained a Buy rating on Tenaya Therapeutics and keeping the price target...

2M ago

TNYA

Promising Pipeline and Financial Prudence Drive Buy Rating for Tenaya Therapeutics

Leerink Partners analyst Mani Foroohar has reiterated their bullish stance on TNYA stock, giving a Buy rating yesterday....

2M ago

TNYA

Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c)

“During the first half of 2025, we achieved target enrollment in our ongoing gene therapy clinical trials of...

2M ago

TNYA

Tenaya receives reviews from independent DSMB to advance TN-201, TN-401

Tenaya Therapeutics (TNYA) announced positive endorsements from each trial’s independent Data Safety and Monitoring Board, DSMB, to proceed...

2M ago

TNYA

Tenaya Therapeutics announces it will present five abstracts as ASGCT 2025

Tenaya Therapeutics (TNYA) announced that it will present five abstracts at the upcoming American Society of Gene and...

5M ago

TNYA

TNYA FAQ

What was Tenaya Therapeutics’s price range in the past 12 months?

Tenaya Therapeutics lowest stock price was $0.36 and its highest was $4.01 in the past 12 months.

What is Tenaya Therapeutics’s market cap?

Tenaya Therapeutics’s market cap is $280.32M.

When is Tenaya Therapeutics’s upcoming earnings report date?

Tenaya Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 28 days.

How were Tenaya Therapeutics’s earnings last quarter?

Tenaya Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.049.

Is Tenaya Therapeutics overvalued?

According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tenaya Therapeutics pay dividends?

Tenaya Therapeutics does not currently pay dividends.

What is Tenaya Therapeutics’s EPS estimate?

Tenaya Therapeutics’s EPS estimate is -0.15.

How many shares outstanding does Tenaya Therapeutics have?

Tenaya Therapeutics has 162,976,100 shares outstanding.

What happened to Tenaya Therapeutics’s price movement after its last earnings report?

Tenaya Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went down -1.493%.

Which hedge fund is a major shareholder of Tenaya Therapeutics?

Currently, no hedge funds are holding shares in TNYA

Tenaya Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-85.21%

Trailing 12-Months

Asset Growth

-25.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tenaya Therapeutics

Tenaya Therapeutics (TNYA) is a biotechnology company focused on discovering, developing, and delivering curative therapies for heart disease. The company operates within the biopharmaceutical sector and is committed to advancing a pipeline of novel therapies aimed at addressing the underlying causes of various forms of heart disease through gene therapy, cellular regeneration, and precision medicine approaches.

Tenaya Therapeutics (TNYA) Earnings & Revenues

Historic Earnings Reports

TNYA Stock 12 Month Forecast

Average Price Target

$10.14

▲(489.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","41":"$41","-1":"-$1","9.5":"$9.5","30.5":"$30.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,9.5,20,30.5,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,4.073846153846154,7.067692307692308,10.061538461538463,13.055384615384616,16.049230769230768,19.043076923076924,22.03692307692308,25.03076923076923,28.024615384615387,31.018461538461537,34.012307692307694,37.00615384615385,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,1.776923076923077,2.473846153846154,3.1707692307692312,3.867692307692308,4.564615384615385,5.261538461538462,5.958461538461539,6.655384615384616,7.352307692307693,8.04923076923077,8.746153846153847,9.443076923076925,{"y":10.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.08,1.2276923076923079,1.3753846153846154,1.523076923076923,1.6707692307692308,1.8184615384615386,1.9661538461538461,2.1138461538461537,2.2615384615384615,2.4092307692307693,2.556923076923077,2.7046153846153844,2.852307692307692,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >